Alterity Therapeutics (NASDAQ:ATHE) Stock Rating Upgraded by Zacks Research

Alterity Therapeutics (NASDAQ:ATHE) was upgraded by investment analysts at Zacks Research to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

A number of other brokerages have also recently issued reports on ATHE. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Monday, April 20th. LADENBURG THALM/SH SH assumed coverage on shares of Alterity Therapeutics in a research note on Tuesday. They set a “buy” rating and a $10.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Alterity Therapeutics Price Performance

NASDAQ ATHE opened at $4.88 on Wednesday. Alterity Therapeutics has a 12 month low of $4.14 and a 12 month high of $350.00. The stock’s fifty day moving average price is $4.31 and its 200-day moving average price is $3.69.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new stake in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.25% of Alterity Therapeutics at the end of the most recent reporting period. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.